VivoSeq
Oncology

Leukemia, Myeloid, Acute

24

Pipeline Programs↗

9

Active Trials↗

12

Companies Involved↗

Leukemia, Myeloid, Acute is an emerging landscape with 24 programs across 12 companies. The most active players are Novartis, Teva, Syndax Pharmaceuticals. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

11/100

Mech. Concentration

14/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 1Teva logo

Teva

1 program

Phase 2S

Syndax Pharmaceuticals

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

9

clinical trials

Recruiting5 · 56%
Active, not recruiting2 · 22%
Not yet recruiting1 · 11%
Enrolling by invitation1 · 11%

Clinical Trials

Trial Activity

9 trials

Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD33 Linked to TCRζ And 4-1BB Signaling Domains In Combination With CD33KO-HSPC In Subjects With Refractory Or Relapsed Acute Myeloid Leukemia
Recruiting·UUniversity of Pennsylvania·Phase 1·NCT05945849·16 enrolled
To Evaluate Safety and Efficiency of AZA Combined With Chidamide as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation：A Multicenter, Single-arm Study
Recruiting·ZZhujiang Hospital·Preclinical·NCT05270200·40 enrolled
A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Recruiting·OOrca Biosystems, Inc.·Phase 2·NCT07216443·80 enrolled
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06852222·600 enrolled
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT06651229·155 enrolled
A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT05453903·196 enrolled
A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy
Active, not recruiting·PPETHEMA Foundation·Phase 3·NCT04090736·302 enrolled
T2023-004 Phase 2 Trial of Revumenib (SNDX-5613) in Combination With FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged Acute Myeloid Leukemia
Not yet recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 2·NCT07686107·24 enrolled
An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring
Enrolling by invitation·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT06788509·120 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)